Johnson & Johnson announced it will convert two 340B drugs to a rebate model for hospitals.
Breaking News
J&J Announces Plans to Shift Certain 340B Discounts to Rebate Model, Prompting Fierce Backlash from Providers, Regulators
Views
In a move that would fundamentally alter the 340B program, pharmaceutical giant Johnson & Johnson (J&J) told hospitals this morning [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
